Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders' In Journal of Medic...

Contineum Therapeutics, Inc. Class A

Contineum Therapeutics, Inc. Class A

CTNM

0.00

- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF)

- Blocking LPAR1 inhibits key steps in the fibrosis pathway with potential targets in several therapeutic indications

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.